KP-10614

KP-10614 is a potent, orally active platelet aggregation inhibitor. KP-10614 inhibits platelet aggregation induced by ADP with IC50 of 1 nM. KP-10614 causes dose-dependent inhibition of ex vivo platelet aggregation in rats. KP-10614 shows antithrombotic effects in various thrombosis models. KP-10614 can be used for thrombotic diseases research[1].

Product Specifications

CAS Number

[130273-99-3]

UNSPSC

12352211

Target

Others

Related Pathways

Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

CCC#CC[C@H](C)[C@H](O)/C=C/[C@@H]1[C@]2([H])[C@@](C[C@H]1O)([H])C=C(C2)/C=C\CCC(O)=O

Molecular Formula

C23H32O4

Molecular Weight

372.50

References & Citations

[1]Kanayama T, et al. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog. J Pharmacol Exp Ther. 1990 Dec;255 (3) :1210-7.